What is the story about?
What's Happening?
Aphios Corporation has been awarded a Small Business Innovation Research (SBIR) Phase I grant from the National Center for Complementary & Integrative Health (NCCIH) of the National Institutes of Health (NIH). The grant supports the development of Zindol®, a botanical drug derived from ginger, aimed at treating chemotherapy-induced nausea and vomiting (CINV). CINV affects up to 70% of adult patients receiving chemotherapy, and current treatments often lead to debilitating side effects. Zindol® has shown significant efficacy in reducing nausea in clinical studies, outperforming existing treatments like Zofran® without adverse effects.
Why It's Important?
The development of Zindol® represents a significant advancement in the treatment of CINV, offering a potentially safer and more effective alternative to current synthetic antiemetics. This botanical drug could improve the quality of life for cancer patients by reducing nausea and vomiting, which are common side effects of chemotherapy. The grant validates the promise of Zindol® as a therapeutic option, potentially reducing treatment costs and improving patient compliance with chemotherapy regimens.
What's Next?
Aphios plans to pursue further development of Zindol®, including Phase II IND-enabling toxicology studies and future Phase III clinical trials. The goal is to license the drug to a strategic pharmaceutical partner, addressing the growing antiemetics market. Successful development could lead to widespread adoption of Zindol® as a preferred treatment for CINV, enhancing patient outcomes and expanding therapeutic options in oncology.
AI Generated Content
Do you find this article useful?
